Important Information
If you are interested in applying for this study, please:
- Read the study description and study information document.
- Review the Visit Planner dates in your location and confirm that you are available for the stated dates.
- If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
- If you have already registered with us, answer the pre-screening questions listed below and submit your interest.
We will then contact you to check your suitability.
Study Description
New Zealand Clinical Research is trialling an investigational medicine that could help people with obesity.
Worldwide, obesity and type 2 diabetes effects approximately 12% of adults. This rate continues to grow every year. The two conditions are closely linked and can lead to serious consequences and an array of metabolic, cardiovascular, and other conditions. This impacts the health-associated quality of life and is of significant cost for healthcare systems around the world.
Lifestyle modification, including diet, exercise, and behavioural change, remain key in the initial management of obesity. Any weight loss achieved with lifestyle interventions alone is challenging to maintain.
The study medicine, ARO-INHBE, is being investigated to see if it can help people with obesity by targeting the liver cells to reduce Activin E protein levels. This protein is involved in the regulation of fat (lipid) storage and breakdown of fat in the tissue (lipolysis). It is hoped that ARO-INHBE may reduce fat storage and improve fat breakdown in the body and improve blood sugar levels in people with obesity. Utilising a combination treatment approach with GLP-1 drugs, ARO-INHBE is being evaluated to determine whether it can provide an improved side effect profile and better health outcome for people affected by this condition.
This is an investigational medicine because it has not been approved by MedSafe or other drug regulatory authorities.
Study Candidates
Healthy Males and Females
- Aged between 18-65
- BMI (Body Mass Index) between 30-50 kg/m2
- Non-smokers or ex-smokers
- Weigh no more than 159kg
- Some Medications allowed
- Have at least one unsuccessful attempt to lose weight via lifestyle changes (e.g. reduced calorie diets, increasing exercise, etc.).
What is Involved?
Study Visits: 2-night stay + 15 clinic visits
Reimbursement:
Cohort 1As: Up to $6,700 before tax
Cohort 1A: Up to $7,300 and $200 per additional biopsy before tax